Altria Group, Inc. Investigation
Company: Altria Group, Inc.
Ticker: (NYSE) MO
Join the Altria Group, Inc. Investigation
Investigation Details
Altria Group shareholders lost money on July 30, 2026 when the stock fell sharply after the Company reported second-quarter results that came in below Wall Street consensus on both earnings and revenue, and then lowered its full-year outlook.
On the Company's Q1 2026 earnings call held April 30, 2026, Chief Financial Officer Sal Mancuso stated: "We reaffirm our expectation to deliver 2026 full-year adjusted diluted EPS in a range of $5.56 to $5.72." That range was subsequently revised downward following the second-quarter report.
Altria's oral nicotine pouch business sits at the center of the Company's smoke-free growth strategy and the regulatory exposure attached to it. On the same April 30, 2026 call, Chief Executive Officer Billy Gifford described on! PLUS as "the first and only product authorized under the FDA's pilot program" and stated that the science behind additional pending applications "provides a basis for FDA authorization within the 180-day statutory time line." The investigation concerns whether Altria adequately disclosed the regulatory and financial risks tied to those statements.